Is Tumor Mutation Burden a predictive Marker for AJCC Stage II Melanoma?

被引：0
|
作者：
Sinnberg, T. [1 ]
Niessner, H. [1 ]
Amaral, T. [1 ,2 ]
Eigentler, T. [1 ]
Schroeder, C. [3 ]
Lindner, E. S. [3 ]
Hilke, F. J. [3 ,4 ]
Bonzheim, I. [5 ]
Fend, F. [5 ]
Riess, O. [3 ]
Garbe, C. [1 ]
机构：
[1] Univ Hautklin Tubingen, Zentrum Dermatoonkol, Tubingen, Germany
[2] Portuguese Air Force, Hlth Care Direct, Lisbon, Portugal
[3] Univ Klinikum Tubingen, Inst Med Genet & Angew Genom, Tubingen, Germany
[4] Charite Univ Med Berlin, Dermatol, Berlin, Germany
[5] Univ Klinikum Tubingen, Inst Pathol, Tubingen, Germany
来源：
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT | 2020年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
FV34
引用
收藏
页码：19 / 19
页数：1
相关论文
共 50 条
  • [41] Stage IIIA melanoma with isolated tumor cells in lymph nodes: Time for reviewing the AJCC v8 classification
    Amaral, T. M. S.
    Nanz, L.
    Stadler, R.
    Forschner, A.
    Meiwes, A.
    Meraz-torres, F.
    Wolfsperger, F.
    Chatziioannou, E.
    Flatz, L.
    Garbe, C.
    Leiter-Stoppke, U.
    ANNALS OF ONCOLOGY, 2023, 34 : S673 - S674
  • [42] Gender Disparity and Mutation Burden in Metastatic Melanoma
    Gupta, Sameer
    Artomov, Mykyta
    Goggins, William
    Daly, Mark
    Tsao, Hensin
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2015, 107 (11):
  • [43] Tumor mutation burden combined with tumor markers as predictive prognostic biomarkers for neoadjuvant chemotherapy in patients with gastric cancer
    Jia, Yongning
    Zhu, Honglin
    Pang, Fei
    Shan, Fei
    Li, Shuangxi
    Dong, Lei
    Ma, Tonghui
    Li, Ziyu
    CANCER RESEARCH, 2020, 80 (16)
  • [44] Predictive Significance of Combined Plasmatic Detection of BRAF Mutations and S100B Tumor Marker in Early-Stage Malignant Melanoma
    Polivka, Jiri
    Gouda, Mohamed A.
    Sharif, Mahyar
    Pesta, Martin
    Huang, Helen
    Treskova, Inka
    Woznica, Vlastimil
    Windrichova, Jindra
    Houfkova, Katerina
    Kucera, Radek
    Fikrle, Tomas
    Ricar, Jan
    Pivovarcikova, Kristyna
    Topolcan, Ondrej
    Janku, Filip
    CANCER MEDICINE, 2024, 13 (19):
  • [45] Tumor mutational burden as a potential predictive marker for the efficacy of immunotherapy in advanced gastric cancer.
    Jang, Jae Yeon
    Jeong, Sun Young
    Kim, Seung Tae
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 324 - 324
  • [46] Tumor-mutation burden as a marker for immunotherapy of pancreatic cancer: the case report and literature review
    Zhu, Peng-Fei
    Chen, Yun-Wang
    Wang, Ming-Xing
    Deng, Ya-Ya
    Pan, Shuang-Yue
    Chen, Zhe-Ling
    Yang, Liu
    ANTI-CANCER DRUGS, 2022, 33 (01) : E822 - E827
  • [47] Intratumoral neutrophils, plasmacytoid dendritic cells, and pSTAT3 in AJCC stage I/II melanoma prognosis.
    Jensen, T. O.
    Schmidt, H.
    Moller, H. J.
    Donskov, F.
    Hoyer, M.
    Sjoegren, P.
    Christensen, I. J.
    Steiniche, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [48] Factors associated with worse outcome for patients with AJCC stage IIC relative to stage IIIA melanoma
    Kim, Caroline C.
    Najita, Julie S.
    Tan, Sally Yi-Meng
    Varada, Sowmya
    Tong, Lana X.
    Dunbar, Haili
    Lee, Mee-young
    Seery, Virginia J.
    Buchbinder, Elizabeth Iannotti
    Tawa, Nicholas E.
    Fuller, Jennifer
    Frankenthaler, Robert Andrew
    McDermott, David F.
    Lee, Sandra J.
    Atkins, Michael B.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [49] US BURDEN OF ILLNESS ASSOCIATED WITH ADJUVANT THERAPY FOR STAGE I-II MELANOMA
    Houts, A. C.
    Ward, M.
    Oglesby, A.
    Walker, M. S.
    Saverno, K.
    VALUE IN HEALTH, 2015, 18 (03) : A215 - A215
  • [50] Vitronectin and dermcidin serum levels predict the metastatic progression of AJCC I-II early-stage melanoma
    Ortega-Martinez, Idoia
    Gardeazabal, Jesus
    Erramuzpe, Asier
    Sanchez-Diez, Ana
    Cortes, Jesus
    Garcia-Vazquez, Maria D.
    Perez-Yarza, Gorka
    Izu, Rosa
    Luis Diaz-Ramon, Jose
    de la Fuente, Ildefonso M.
    Asumendi, Aintzane
    Boyano, Maria D.
    INTERNATIONAL JOURNAL OF CANCER, 2016, 139 (07) : 1598 - 1607
12345